Compare DraftKings Inc (DKNG) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs DexCom, Inc. — how do they compare? DraftKings Inc trades at $25.41 (market cap $12.58B), while DexCom, Inc. trades at $90.64 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 2.7× DraftKings Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| DKNG | DXCM | |
|---|---|---|
Market Cap | $12.58B | $33.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $89.53 |
52-Week Low | $20.72 | $54.84 |
Enterprise Value | $13.51B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $25.79, up 6.24% on the day, with a bullish technical signal and strong analyst consensus. Revenue grew to $6.05 billion in 2025, though recent quarters show earnings misses. The company is expanding into prediction markets, with CEO Jason Robins highlighting rapid growth ahead of the NFL season (Bloomberg Technology, 2026-08-07).
The outlook is mixed: strong revenue growth and positive cash flow from operations contrast with high valuation multiples and recent profitability challenges. Key risks include competition from prediction markets and promotional costs pressuring margins. The consensus price target of $34.00 suggests upside potential if execution improves.
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
